代谢相关的共同研究及授权契约:2019年～2025年

代谢研究和授权协议提供了前所未有的机会，可以全面了解世界领先的生物製药公司的代谢机会。

本报告已全面修订和更新，提供 2019 年至 2025 年 576 项代谢相关交易的详细资讯。

此报告提供双方宣布的交易付款条款。这些数据为付款条款和其他贸易条款提供了有用的见解。

了解潜在合作伙伴谈判交易条款的弹性可以为谈判过程提供重要的见解，让您了解谈判条款时会发生什么。许多小型企业可能会想要详细的付款条款，但当涉及到如何产生付款以及如何转移权利时，细节决定成败。

本报告提供了当前协议交易和合作资料库中记录的自 2019 年以来宣布的合作和许可协议的综合列表，包括可用的财务条款，并包含公司及其合作伙伴向 SEC 提交的实际许可协议文件的在线副本链接。

报告的第一章提供了代谢贸易和商业趋势的快照。第 1 章对报告进行了介绍，第 2 章分析了 Metabolic 的交易趋势。

第 3 章介绍了代谢空间中完成的交易的财务条款以及发展阶段。交易按标题价值、预付款、里程碑付款和特许费率列出并分为几个部分。

第 4 章回顾了在代谢交易中最活跃的 25 家生物製药公司。对于美国证券交易委员会已公开宣布协议的案件，可以透过这些连结在当前协议交易和联盟资料库中线上存取该协议。

第 5 章对 2019 年以来签署和宣布的代谢相关交易进行了全面深入的回顾，并提供合约文件。每个交易标题都透过网路连结连结到实际合约文件的线上版本，以便在需要时轻鬆存取每个合约文件。

第 6 章提供了与代谢相关的病例的综合目录，按治疗目标列出。

该报告还包含大量图表和图形，说明了自 2019 年以来与代谢相关的病例趋势和活动。

此外，我们还提供按公司 A-Z 和技术类型组织的综合贸易目录。每个交易标题都提供了一个指向交易记录在线版本的网络链接，并在可用的情况下提供合同文件，从而可以轻鬆、按需访问每个交易文件。

主要优点

代谢相关的研究合作和授权协议为读者提供了以下主要好处：

• 了解 2019 年及以后的合约趋势
• 浏览代谢合作与许可机会
• 基准分析 - 确定交易的市场价值
• 财务条款 – 预付款、里程碑付款、特许权使用费
• 依公司 A-Z、治疗目标、技术类型划分的交易目录
• 大额交易金额
• 最活跃的交易者
• 确定每笔交易的资产和条款
• 查阅合约文件－洞察交易结构
• 尽职调查 - 评估拟议交易条款对合作伙伴公司的适用性。
• 节省数百小时的研究时间

研究范围

• 代谢研究合作与许可协议旨在更深入地了解全球领先生物製药公司签署的代谢趋势和交易结构。

回报内容

• 生物製药产业代谢相关交易趋势
• 合作与授权协议架构概述
• 涵盖药品和生物技术的代谢相关交易记录目录
• 代谢相关领域的重大交易
• 最活跃的代谢许可交易制定者

目录

摘要整理

第1章 简介

第2章 代谢相关的交易趋势

• 简介
• 多年的代谢相关的联盟
• 各交易类型的代谢联盟
• 各业界的代谢相关的联盟
• 各开发阶段的代谢相关的联盟
• 各技术类型的代谢相关的联盟
• 各治疗适应症的代谢相关的联盟

第3章 代谢相关的联盟的金融交易条件

• 简介
• 公开代谢相关的联盟相关财务条件
• 代谢合作伙伴的标题价值
• 代谢相关的交易预付款
• 代谢相关的交易的里程金
• 代谢权利金费率

第4章 主要代谢相关的交易和交易负责人

• 简介
• 最活跃的代谢伙伴
• 最活跃的代谢交易者名单
• 各价值排名的顶级代谢交易

第5章 代谢契约文件名录

• 简介
• 已签约的代谢联盟交易

第6章 按治疗标的代谢相关的交易

• 简介
• 按治疗标的代谢相关的交易
• 交易名录
• 交易目录 - 新陈代谢交易（按公司划分）（2019-2025 年）
• 交易目录 - 按技术类型划分的代谢交易（2019-2025 年）
• 定义交易类型
• 关于 Biopharma Research Ltd
• 当前合作伙伴关係
• 当前合约
• Current Partnering 的最新报告标题

Metabolic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the metabolic deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 576 metabolic deals from 2019 to 2025.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of metabolic dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in metabolic dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the metabolic field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in metabolic dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of metabolic deals signed and announced since 2019 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of metabolic deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in metabolic deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Metabolic Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2019
• Browse metabolic collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Metabolic Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of metabolic trends and structure of deals entered into by leading biopharma companies worldwide.

Metabolic Collaboration and Licensing Deals includes:

• Trends in metabolic dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of metabolic deal records covering pharmaceutical and biotechnology
• The leading metabolic deals by value
• Most active metabolic licensing dealmakers

In Metabolic Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Metabolic Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in metabolic dealmaking

• 2.1. Introduction
• 2.2. Metabolic partnering over the years
• 2.3. Metabolic partnering by deal type
• 2.4. Metabolic partnering by industry sector
• 2.5. Metabolic partnering by stage of development
• 2.6. Metabolic partnering by technology type
• 2.7. Metabolic partnering by therapeutic indication

Chapter 3 - Financial deal terms for metabolic partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for metabolic partnering
• 3.3. Metabolic partnering headline values
• 3.4. Metabolic deal upfront payments
• 3.5. Metabolic deal milestone payments
• 3.6. Metabolic royalty rates

Chapter 4 - Leading metabolic deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in metabolic partnering
• 4.3. List of most active dealmakers in metabolic
• 4.4. Top metabolic deals by value

Chapter 5 - Metabolic contract document directory

• 5.1. Introduction
• 5.2. Metabolic partnering deals where contract document available

Chapter 6 - Metabolic dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by metabolic therapeutic target
• Deal directory
• Deal directory - Metabolic deals by company A-Z 2019 to 2025
• Deal directory - Metabolic deals by technology type 2019 to 2025
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Metabolic partnering since 2019
• Figure 2: Metabolic partnering by deal type since 2019
• Figure 3: Metabolic partnering by industry sector since 2019
• Figure 4: Metabolic partnering by stage of development since 2019
• Figure 5: Metabolic partnering by technology type since 2019
• Figure 6: Metabolic partnering by indication since 2019
• Figure 7: Metabolic deals with a headline value
• Figure 8: Metabolic deals with upfront payment values
• Figure 9: Metabolic deals with milestone payment
• Figure 10: Metabolic deals with royalty rates
• Figure 11: Active metabolic dealmaking activity since 2019
• Figure 12: Top metabolic deals by value since 2019